 | Up a level |
Leone, Jose P; Cole, Bernard F; Regan, Meredith M; Thürlimann, Beat; Coates, Alan S; Rabaglio, Manuela; Giobbie-Hurder, Anita; Gelber, Richard D; Ejlertsen, Bent; Harvey, Vernon J; Neven, Patrick; Láng, Istvan; Bonnefoi, Herve; Wardley, Andrew; Goldhirsch, Aron; Di Leo, Angelo; Colleoni, Marco; Vaz-Luis, Ines; Lin, Nancy U (2021). Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Cancer, 127(5), pp. 700-708. Wiley 10.1002/cncr.33318
Rabaglio, Manuela; Sun, Zhuoxin; Maibach, Rudolf; Giobbie-Hurder, Anita; Ejlertsen, Bent; Harvey, Vernon J; Neven, Patrick; Láng, István; Bonnefoi, Hervé; Wardley, Andrew; Ruepp, Barbara; Castiglione, Monica; Coates, Alan S; Gelber, Richard D; Goldhirsch, Aron; Colleoni, Marco; Thürlimann, Beat; Regan, Meredith M (2020). Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast cancer research and treatment, 185(3), pp. 697-707. Springer 10.1007/s10549-020-05981-z
Regan, Meredith M; Neven, Patrick; Giobbie-Hurder, Anita; Goldhirsch, Aron; Ejlertsen, Bent; Mauriac, Louis; Forbes, John F; Smith, Ian; Láng, István; Wardley, Andrew; Rabaglio, Manuela; Price, Karen N; Gelber, Richard D; Coates, Alan S; Thürlimann, Beat; BIG 1-98 Collaborative Group, ; International Breast Cancer Study Group (IBCSG), (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet oncology, 12(12), pp. 1101-8. Oxford: Elsevier 10.1016/S1470-2045(11)70270-4
